At the American Association of Pharmaceutical Scientists (AAPS) annual meeting, Boehringer Ingelheim announced results from a Phase 1 study of BI695501, its biosimilar candidate for Humira (adalimumab). According to a company press release, data presented in a poster presentation at the meeting showed safety, tolerability and immune response were comparable among study participants treated with BI695501 or adalimumab.

Click here for full press release